Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases

Table 1 Overview of the OAIs, excipients and packaging used in the compounded formulations

OAIs	Supplier
L-arginine	Fagron, Waregem, Belgium
L-carnitine	Fagron, Waregem, Belgium
Chenodesoxycholic acid	BOC Sciences Creative Dynamics, Shirley, United States
Primaquine phosphate	BOC Sciences Creative Dynamics, Shirley, United States
Pyridoxal phosphate	Inresa, Bartenheim, France
Sodium benzoate	Fagron, Waregem, Belgium
Sodium perchlorate^a	Merck, Darmstadt, Germany
Sodium phenylbutyrate	Fyrklovern Scandinavia AB, Mönsteras, Sweden
Excipients	Supplier
Aurantii amari epicarp et mesocarp tinctura	Conforma, Destelbergen, Belgium
Sirupus simplex	Conforma, Destelbergen, Belgium
Methyl paraben	Fagron, Waregem, Belgium
Propyl paraben	Fagron, Waregem, Belgium
Mannitol	Fagron, Waregem, Belgium
Colloidal silicon dioxide	Fagron, Waregem, Belgium
Packaging	Supplier
Hard gelatine capsules	Capsugel, Bornem, Belgium
Glass bottles 100 ml	Aca Pharma, Nazareth, Belgium
Plastic opaque cups	Aca Pharma, Nazareth, Belgium

^aSodium perchlorate is not an OAI but was included in the study as an unlicensed molecule regularly compounded by hospital pharmacists for extemporaneous use

ISSN: 1750-1172